RenovoRx Q1 net loss widens 45% to $3.52 million; revenue rises 186% to $563,000

• RenovoRx posted a net loss of USD 3.52 million for the quarter ended March 31, 2026, widening 45% from a year earlier.
• Revenue climbed to USD 563,000, up 186%, as RenovoCath sales accelerated; gross profit rose to USD 479,000.
• Operating loss widened to USD 3.47 million, while selling, general and administrative expense increased to USD 2.72 million, up 73%.
• Cash and cash equivalents totaled USD 12.4 million at March 31, following a USD 10 million private placement that included common stock, pre-funded warrants, and revenue milestone warrants.
• RenovoCath rollout expanded to 16 active commercial cancer centers as of May 6, 2026, with a pipeline of 32 additional centers; TIGeR-PaC Phase III trial enrollment was 106 patients as of May 14, 2026, with enrollment expected to close by end of June and final data targeted for mid to late 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-224100), on May 14, 2026, and is solely responsible for the information contained therein.